In an original CTA or IND for a FIH trial, companies are primarily required to provide information on the safety and quality of the drug (or biologic) to support clinical studies. These summaries are expected in regulatory submissions and are particularly useful for supporting the mechanism of action of drugs and biologics.
08-08 December 2022